

IN A CRISIS, ARE YOU AS PREPARED AS YOU COULD BE?

Cause of mortality: **CAR ACCIDENT**

1 in 17,625¹

At first glance, wearing a seatbelt seems to be enough. But consider the bigger picture, buying better tires could be what makes the difference.



Cause of mortality: **DROWNING**

1 in 83,543¹

At first glance, knowing how to swim seems to be enough. But consider the bigger picture, paying for a lifeguard could be what makes the difference.



Cause of mortality: **FIRE**

1 in 91,149¹

At first glance, smoke detectors seem to be enough. But consider the bigger picture, investing in a fire extinguisher could be what makes the difference.



Cause of mortality: **FORCES OF NATURE**

1 in 236,211¹

At first glance, weather monitoring seems to be enough. But consider the bigger picture, funding early warning systems could be what makes the difference.



Cause of mortality: **FALLING DOWN STEPS**

1 in 180,188¹

At first glance, installing a railing seems to be enough. But consider the bigger picture, spending a little extra on steps with grip could be what makes the difference.



TURN OVER

These ratios are statistical averages based on the US population. They do not reflect the odds of death for a particular person from a particular cause.

Chances of a malignant hyperthermia (MH) crisis:

1 in 10,000
for children

1 in 50,000
for adults²

Chances of a patient dying during an MH crisis:

approximately 1 in 10.³

Whether it's highly unlikely or even rare, any crisis with a possibly severe outcome deserves the utmost consideration.

Consider the bigger picture, for everyone involved.

Time is of the essence in an MH crisis. Standard dantrolene sodium IV products are more involved in terms of vials, personnel, and time.⁴⁻⁶ But RYANODEX® (dantrolene sodium) for injectable suspension is fast to reconstitute and administer,^{4,7} and time is what makes all the difference.

RYANODEX® FACTS:

- It can be reconstituted in 1 minute^{4,7}
- In many cases, only one vial is required^{4,8}
- It can be administered by just one anesthesia provider⁷

These statistics are based on the number of adults and children undergoing procedures requiring anesthesia.



INDICATION

RYANODEX® (dantrolene sodium) for injectable suspension is indicated for the treatment of malignant hyperthermia in conjunction with appropriate supportive measures, and for the prevention of malignant hyperthermia in patients at high risk.

IMPORTANT SAFETY INFORMATION

RYANODEX® (dantrolene sodium) for injectable suspension is not a substitute for appropriate supportive measures in the treatment of malignant hyperthermia (MH), including:

- Discontinuing triggering anesthetic agents
- Increasing oxygen
- Managing the metabolic acidosis
- Instituting cooling when necessary
- Administering diuretics to prevent late kidney injury due to myoglobinuria (the amount of mannitol in RYANODEX® is insufficient to maintain diuresis)

Precautions should be taken when administering RYANODEX® preoperatively for the prevention of malignant hyperthermia, including monitoring vital signs, avoiding known triggering agents, and monitoring for early clinical and metabolic signs of malignant hyperthermia that may indicate additional treatment is needed.

The administration of dantrolene sodium is associated with loss of grip strength and weakness in the legs, as well as drowsiness, dizziness, dysphagia, dyspnea, and decreased inspiratory capacity. Patients should not be permitted to ambulate without assistance until they have normal strength and balance. Care must be taken to prevent extravasation of RYANODEX® into the surrounding tissue due to the high pH of the reconstituted RYANODEX® suspension and potential for tissue necrosis.

References: 1. The Risk Communication Institute website. Examples using the Risk Perspective Scale. 2007. Available at: <http://www.riskcomm.com/visualaids/riskscale/datasources.php>. Accessed March 2, 2015. 2. Rosenberg H, Sambuughin N, Riazi S, Dirksen R. Malignant Hyperthermia Susceptibility. 2003 Dec 19 [updated 2013 Jan 31]. In: Pagon RA, Adam MP, Ardinger HH, et al, editors. *GeneReviews* [Internet]. Seattle (WA): University of Washington, Seattle;1993-2014. 3. Rosero EB, Adesanya AO, Timaran CH, Joshi GP. Trends and outcomes of malignant hyperthermia in the United States, 2000 to 2005. *Anesthesiology*. 2009;110(1):89-94. 4. RYANODEX [package insert]. Woodcliff Lake, NJ: Eagle Pharmaceuticals, Inc.; 2014. 5. Dantrium Intravenous [package insert]. Rochester, MI: JHP Pharmaceuticals, LLC; 2008. 6. Revonto [package insert]. Louisville, KY: US WorldMeds, LLC; 2011. 7. Data on file. Eagle Pharmaceuticals, Inc. 8. Malignant Hyperthermia Association of the United States website. Managing an MH Crisis. Available at: <http://www.mhaus.org/healthcare-professionals/managing-a-crisis>. Accessed May 27, 2014.

Please see full Prescribing Information for complete dosage and administration information.

© 2015 Eagle Pharmaceuticals, Inc. All rights reserved.
50 Tice Blvd, Suite 315, Woodcliff Lake, NJ 07677

RYN15-0002-01 5/2015

Ryanodex®
(dantrolene sodium)
for injectable suspension